
There are many risk factors for the development of Peripheral Artery Disease (PAD) and quite a few medical conditions that contribute to greater morbidity and higher rates of complications. Smoking is the most prominent modifiable risk factor, while diabetes takes the first place as both a risk factor and detrimental comorbid condition. There are however contenders which, although less known, are as serious or, in certain aspects, even more so, such as Chronic Kidney Disease (CKD).
Peripheral Artery Disease (PAD), or Lower Extremity Artery Disease (LEAD) as it is also known, could very well be called a modern-day disease, although this is technically not true as we now have archaeological evidence that it was already present in ancient times [1]. We are talking of course from the perspective of rise in modifiable risk factors, which contribute to the greater prevalence and severity of symptoms. Smoking, hyperlipidaemia, hypertension, a lack of regular physical activity and an unhealthy weight are prime examples [2-7]. These, along with diabetes mellitus and the general ageing of the population, are the main culprits for 236.62 million patients in 2015 (up from 202 million in 2010) and the continuing projected rise in the prevalence of PAD [8, 9].
Increasing numbers of patients naturally translate to a greater workload for physicians and financial expenses for the healthcare systems. Additionally, comprehensive treatment of PAD often requires synergetic approach, not only on the part of general practitioners (patient’s personal physician) and cardiologists, but also other healthcare professionals like diabetologists (endocrinologists), wound care providers and nephrologists. The latter are usually well acquainted with the harmful effects of renal insufficiency on the cardiovascular system and, in particular, its association with Coronary Artery Disease (CAD), but may be less aware of dangers of other conditions like PAD.
Are patients with CKD at greater risk for PAD?
Cardiovascular Diseases (CVDs), especially those of an atherosclerotic type, are in general far more common in those with CKD than in individuals without renal issues [10]. There’s more: patients with CKD are more likely to die from CVD complications than they are to progress to End-Stage Renal Disease (ESRD) [11, 12]. A fair share of those complications is connected with PAD and patients with CKD are at more than two time the risk of developing this insidious disease than those with normal renal function [13]. Those who already have both diseases are at a markedly increased short-term risk of myocardial infarction and stroke, have greater mortality rates than those with either disease and suffer worse and more frequent complications post revascularisation procedures [14, 15].
Other notable complications at the intersection of CKD and PAD are incompressible arteries. Patients with CKD are more likely to suffer from arterial media calcification (the most common causative mechanism for incompressible arteries), as those with diabetes and rheumatoid arthritis [16, 17, 18]. Accordingly diagnosis of incompressible arteries is associated with greater overall and cardiovascular mortality in haemodialysis patients, while from the perspective of PAD the significance lies in an increased likelihood of misdiagnosis if the Ankle-Brachial (Pressure) Index (ABPI or ABI) assessment method is used [18, 19].
Regardless of which method for measuring PAD is used, be it a Doppler probe/sphygmomanometer combination or the more easy to use and reliable oscillometric-plethysmographic diagnostic device, an abnormally high ABI (generally in the ≥1.30 to 1.40 range) is of little diagnostic value for PAD, but may be an indicator of an increased risk for myocardial infarction [19-22]. A Toe-Brachial Index (TBI) assessment can be used instead as toe arteries are rarely affected by calcification [23].
Despite such overwhelming evidence of disastrous collusion of CKD and PAD, many large PAD epidemiological studies have not included CKD as a risk a risk factor and consequently have not reported information about level of renal function, hindering accurate estimates of prevalence of PAD in patients with CKD [24, 25, 26]. Some studies put that number in between 23 % and 25 %, while others, through the use of the ABI as diagnostic criteria, report much a higher prevalence of up to 35 % [27, 28, 29]. Moreover randomised clinical trials of PAD therapies have often excluded patients with severe renal insufficiency, although they are at highest risk [29].
Patients with CKD or already receiving dialysis should therefore be given comprehensive screening on the basis of inclusion in risk groups (a comprehensive questionnaire tailored especially for nephrologists is invaluable in such instances) and ABI or TBI assessments [30]. The latter is recognised as more sensitive in ESRD patients than the ABI and has additional diagnostic value as a predictor of mortality in dialysis patients [31, 32]. A positive diagnosis on the basis of PAD and TBI is often followed by magnetic resonance angiography to better assess the extent of atherosclerotic lesions and occlusions, although this diagnostic procedure is not without risk. There is evidence that the use of contrast medium in these tests, specifically gadolinium, is associated with development of Nephrogenic Systemic Fibrosis (NSF) in those with severe renal dysfunction [33, 34].
On the other hand there is a marked lack of high-quality evidence when it comes to a proper therapeutic approach for treating PAD in patients with renal insufficiency, or more specifically those on dialysis. In general the joint goals are treatment of PAD and a reduction in cardiovascular risk factors. These may be achieved by secondary risk reduction (lifestyle modification), such as smoking cessation, which improves functional capacity for those with PAD, but there is no evidence that the effect is the same in those with comorbid CKD [35]. The benefits of statin therapy are likewise (currently) unclear [36].
The consequences of a lack of proper and/or timely treatment of PAD are well-known, as are the higher rates of complications in those with comorbid CKD. Untreated PAD may manifest as arterial insufficiency ulcers (ischaemic ulcers/wounds), which can quickly progress into gangrene and Critical Limb Ischaemia (CLI). This end stage of PAD is associated with high amputation rates, from 10 % to 40 % for a 6-month period after diagnosis, and mortality in the ballpark of 20 % in the 6-month period to 50 % in 5 years after diagnosis [37-41].
Revascularisation is usually the only option to save the patient’s limb. Outcomes of such procedures are mixed: in patients with moderate renal insufficiency rates of both successful outcomes and complications are acceptable, while for those undergoing dialysis they were much worse, particularly amputation rates (three times greater than in the first group) [42]. Nevertheless, one thing is certain: there is still much to be done in regards to optimal treatment of PAD in individuals with renal insufficiency.
Patients with CKD are especially at risk for development of PAD and they suffer higher rates of more severe complications and adverse outcomes. Preventive screening is therefore strongly recommended no later than at the commencement of dialysis.
[1] DEGENERATIVE VASCULAR DISEASE IN THE EGYPTIAN MUMMY > https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1034676/
[2] Meta-analysis of the association between cigarette smoking and peripheral arterial disease > https://heart.bmj.com/content/100/5/414
[3] Smoking, Smoking Cessation and Risk of Symptomatic Peripheral Artery Disease in Women: A Prospective Study > https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111942/
[4] Influence of smoking on incidence and prevalence of peripheral arterial disease > https://www.sciencedirect.com/science/article/pii/S0741521404011413
[5] The prevalence of peripheral arterial disease in a defined population > https://pdfs.semanticscholar.org/0594/15ad0ba1e52dc181e40468283e8513542cb9.pdf
[6] Hypertension in peripheral arterial disease > https://www.ncbi.nlm.nih.gov/pubmed/15579058
[7] Association of Body Mass Index With Peripheral Arterial Disease in Older Adults: The Cardiovascular Health Study > https://academic.oup.com/aje/article/174/9/1036/168550/
[8] Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis > https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)61249-0/fulltext
[9] Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis > https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(19)30255-4/fulltext
[10] Kidney Disease as a Risk Factor for Development of Cardiovascular Disease > https://www.ahajournals.org/doi/10.1161/01.HYP.0000102971.85504.7c
[11] Chronic Kidney Disease and the Risk for Cardiovascular Disease, Renal Replacement, and Death in the United States Medicare Population, 1998 to 1999 > https://jasn.asnjournals.org/content/16/2/489.long
[12] Longitudinal Follow-up and Outcomes Among a Population With Chronic Kidney Disease in a Large Managed Care Organization > https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/216833
[13] High Prevalence of Peripheral Arterial Disease in Persons With Renal Insufficiency > https://www.ahajournals.org/doi/full/10.1161/01.CIR.0000114519.75433.DD
[14] Combined Effect of Chronic Kidney Disease and Peripheral Arterial Disease on All-Cause Mortality in a High-Risk Population > https://cjasn.asnjournals.org/content/3/4/1084.long
[15] Impact of Renal Insufficiency on Short-Term Morbidity and Mortality after Lower Extremity Revascularization: Data from the Department of Veterans Affairs’ National Surgical Quality Improvement Program > https://jasn.asnjournals.org/content/14/5/1287.long
[16] Medial arterial calcification in diabetes and its relationship to neuropathy > https://www.ncbi.nlm.nih.gov/pubmed/19756483/
[17] Lower limb arterial incompressibility and obstruction in rheumatoid arthritis > https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1755423/
[18] Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality > https://academic.oup.com/ndt/article/18/9/1731/1842064
[19] Association of High Ankle Brachial Index With Incident Cardiovascular Disease and Mortality in a High-Risk Population > https://ahajournals.org/doi/10.1161/ATVBAHA.115.306657
[20] Reliability of ankle:brachial pressure index measurement by junior doctors > https://www.ncbi.nlm.nih.gov/pubmed/8156330/
[21] Detection of peripheral arterial disease with an improved automated device: comparison of a new oscillometric device and the standard Doppler method > https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973721/
[22] Comparison Of Ankle-Brachial Index (ABI) Measurement Between A New Oscillometric Device (MESI ABPI Md®) And The Standard Doppler Method In The Diagnosis Of Lower Extremity Arterial Disease (LEAD) > http://www.heraldopenaccess.us/fulltext/Non-Invasive-Vascular-Investigation/Comparison-of-Ankle-Brachial-Index-ABI-Measurement-between-a-New-Oscillometric-Device-MESI-ABPI-Md-and-the-Standard-Doppler-Method.php
[23] Ankle Brachial Index, Toe Brachial Index, and Cardiovascular Mortality in Participants With and Without Diabetes Mellitus > https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112146/
[24] Mortality over a period of 10 years in patients with peripheral arterial disease > https://www.ncbi.nlm.nih.gov/pubmed/1729621
[25] Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population > https://www.ncbi.nlm.nih.gov/pubmed/1917239
[26] Intermittent Claudication > https://www.ahajournals.org/doi/full/10.1161/01.CIR.96.1.44
[27] Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients > https://www.ncbi.nlm.nih.gov/pubmed/10886582/
[28] Peripheral Arterial Disease in Patients With End-Stage Renal Disease > https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.105.607390
[29] Peripheral Artery Disease and Chronic Kidney Disease: Clinical Synergy to Improve Outcomes > https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4254470/
[30] Peripheral Arterial Disease: A Guide for Nephrologists > https://cjasn.asnjournals.org/content/2/4/839
[31] Lower-extremity peripheral arterial disease among patients with end-stage renal disease > https://pdfs.semanticscholar.org/4931/7f573333a67ae55bf3fa7407358bf5df0ab6.pdf
[32] The association of the ankle‐brachial index, the toe‐brachial index, and their difference, with mortality and limb outcomes in dialysis patients > https://onlinelibrary.wiley.com/doi/abs/10.1111/hdi.12734
[33] Nephrogenic Systemic Fibrosis: Suspected Causative Role of Gadodiamide Used for Contrast-Enhanced Magnetic Resonance Imaging > https://jasn.asnjournals.org/content/17/9/2359
[34] Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? > https://academic.oup.com/ndt/article/21/4/1104/1932577
[35] The relationship of cigarette smoking to peripheral arterial disease > https://www.ncbi.nlm.nih.gov/pubmed/15580157
[36] Study of Heart and Renal Protection (SHARP) > https://www.kidney-international.org/article/S0085-2538(15)49253-1/fulltext
[37] Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial > https://www.ncbi.nlm.nih.gov/pubmed/16325694
[38] Medical treatment of peripheral arterial disease: a comprehensive review > https://www.ncbi.nlm.nih.gov/pubmed/15525738
[39]The natural history of untreated severe or critical limb ischemia > https://www.jvascsurg.org/article/S0741-5214(15)01625-0/fulltext
[40] Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) > https://www.jvascsurg.org/article/S0741-5214(06)02296-8/fulltext
[41] Chapter I: Definitions, Epidemiology, Clinical Presentation and Prognosis > https://www.ejves.com/article/S1078-5884(11)60009-9/fulltext
[42] Influence of renal insufficiency on limb loss and mortality after initial lower extremity surgical revascularization > https://www.jvascsurg.org/article/S0741-5214(03)01740-3/fulltext